Ignite Creation Date:
2024-05-06 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 2:22 PM
Study NCT ID:
NCT05203445
Status:
RECRUITING
Last Update Posted:
2024-01-25
First Post:
2022-01-10
Brief Title:
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer TNBC or Hormone Receptor-positive HER2-negative Breast Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Phase II of Neoadjuvant Olaparib in Combination With Pembrolizumab in Patients With Triple Negative Breast Cancer TNBC or Hormone Receptor-positive HER2-negative Breast Cancer and Germline Mutations in DNA Damage Repair Genes
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test any good and bad effects of combining the study drugs pembrolizumab and olaparib given before the standard surgical procedure to treat TNBC or HR HER2- breast cancers The study drugs could shrink cancer but they could also cause side effects The study researchers want to find out whether the study drugs will shrink the cancer by a certain percentage compared with its current size which may improve the outcome of surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None